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609relevant in the setting of slower relaxation, as may be observed in
HFpEF patients. Slow incomplete relaxation can be induced by
excessive afterload to such an extent that it leads to marked increases
in ﬁlling pressures.When the ejection fraction is preserved, the effect
of afterload is particularly evident and signiﬁcantly exacerbated at
higher pre-loads (2). Moreover, in contrast to normal hearts, the
myocardium of heart failure patients may exhibit a ﬂat or negative
myocardial relaxation velocity to HR relationship, even at a lower
range of HR (3). Consequently, lowering the HR during early ex-
ercise would prevent the clinical expression of this HR-dependent
relaxation impairment.
Finally, as Reil et al. (4) recently showed, ivabradine decreases
arterial elastance through an enhancement of arterial compliance
and a reduction in HR. This reduction in global LV afterload
could also contribute to the short-term increase in exercise
tolerance described in the ivabradine-treated HFpEF patient
group.
The absence of a negative lusitropic pharmacological action and
the ability to modulate these diastolic function determinants (HR
and afterload) make ivabradine a mechanistically very attractive
drug in HFpEF treatment. Future clinical trials will give the critical
verdict.Mário Santos, MD
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Cardiol 2013;62:1977–85.ReplyEffect of Ivabradine on Heart Failure
With Preserved Ejection FractionWe appreciate the interest of Drs. Santos and Leite-Moreira in our
work (1). We completely agree with their comments regarding the
importance of heart rate (HR) as a contributor to diastolic function.
Ivabradine has a unique position as a negative chronotrope that is
not a negative inotrope. Indeed, the rationale for treatment with
ivabradine in our study was to avoid the reduction in the duration
of diastole that follows from an increase in HR.
Disturbances in the relationship between HR and myocardial
relaxation in failing hearts might represent another aspect supporting
the use of If channel inhibition in this context. Although ivabradine
hasmultiple effects, a direct effect onmyocardial relaxationmay be an
important beneﬁt. In addition, the potential effects of ivabradine on
arterial compliance and afterload in heart failure with preserved
ejection fraction (HFpEF) require, in our view, further evaluation.
The patient selection in our study was focused on patients in
whom exertional dyspnea develops, which is related in part to
shortening of diastole during tachycardia. The clinical effects of
ivabradine are being investigated in a large multicenter study, but
it is likely that this will involve a heterogeneous group. We would
like to draw the attention of readers to the need for studying
well-characterized subgroups of the very heterogeneous entity of
heart failure with preserved ejection fraction.*Thomas H. Marwick, MD, PhD
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